Trump announces 100% chip tariff as Apple ups U.S. investment
Zivo Bioscience, Inc. (ZIVO), a company specializing in biological products with a current market capitalization of $60.29 million, has reported the issuance of new equity shares, according to a recent 8-K filing with the Securities and Exchange Commission.
The company's stock has shown remarkable momentum, gaining 126% over the past six months, according to InvestingPro data. On Monday, the company disclosed that between the filing of its last Form 10-Q on November 14, 2024, and January 22, 2025, it issued a total of 191,698 shares in transactions exempt from public offering.
The company sold 75,000 shares to one accredited investor at $20.19 per share, accumulating gross proceeds of approximately $1.5 million. Additionally, Zivo Bioscience granted 38,478 shares as restricted stock to non-employee members of its board of directors under the 2024 Equity Incentive Plan for Non-Employee Directors.
In a previously filed Form 8-K on January 15, 2025, Zivo Bioscience announced an Exchange Program where it agreed to issue shares to certain investors in return for the cancellation of specific License and Co-Development Participation Agreements and the associated revenue-sharing arrangement. As part of this program, the company has issued 78,320 shares to investors.
The transactions did not involve public offerings, general solicitation, or underwriting discounts. The issued shares were not registered under the Securities Act of 1933, as amended, or state securities laws. Instead, they were offered to "accredited investors" based on exemptions provided by Section 4(a)(2) and Regulation D (Rule 506) of the Securities Act and corresponding state securities laws, which allow for transactions by an issuer not involving a public offering.
As of January 22, 2025, Zivo Bioscience has a total of 3,738,033 shares of common stock outstanding. The company's common stock and warrants are traded on the OTCQB and OTC Pink Sheets under the symbols ZIVO and ZIVOW, respectively.
InvestingPro analysis indicates the company's current financial health score is weak, with a current ratio of 0.17, suggesting potential liquidity challenges. Despite these challenges, the company has achieved impressive revenue growth of nearly 400% in the last twelve months. Subscribers to InvestingPro can access 8 additional key insights about ZIVO's financial position and growth prospects.
This information is based on the latest SEC filing by Zivo Bioscience, Inc. and provides a factual report of the company's recent financial activities without any speculative or subjective content.
In other recent news, Zivo Bioscience reported significant developments including a change in office location and a restructuring of its existing debt. The Nevada-based biotech firm has relocated its principal executive office to Troy, Michigan, from its previous location in Bloomfield Hills, Michigan, as revealed in a recent 8-K filing with the Securities and Exchange Commission (SEC).
In addition to the office move, Zivo Bioscience has also recently restructured its debt by issuing unsecured promissory notes totaling approximately $277,254.38. This financial restructuring involved agreements with three creditors, namely Howard Shapiro, Merger Masters Pension Fund, and Financial Trading Consultants Pension Fund. The repayment of these notes, carrying a nominal interest rate of 1.0% per annum, is set to commence on November 30, 2024, over a 24-month period.
Furthermore, the company reported the sale of 169,022 shares of its common stock to several accredited investors. These transactions took place at prices ranging from $8.34 to $16.31, averaging $10.44 per share. A portion of these shares, specifically 52,802, were sold to related parties at an average price of $9.68 per share.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.